1. Home
  2. ARCC vs EXAS Comparison

ARCC vs EXAS Comparison

Compare ARCC & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARCC
  • EXAS
  • Stock Information
  • Founded
  • ARCC 2004
  • EXAS 1995
  • Country
  • ARCC United States
  • EXAS United States
  • Employees
  • ARCC N/A
  • EXAS N/A
  • Industry
  • ARCC Finance/Investors Services
  • EXAS Medical Specialities
  • Sector
  • ARCC Finance
  • EXAS Health Care
  • Exchange
  • ARCC Nasdaq
  • EXAS Nasdaq
  • Market Cap
  • ARCC 14.0B
  • EXAS 11.6B
  • IPO Year
  • ARCC 2004
  • EXAS N/A
  • Fundamental
  • Price
  • ARCC $21.38
  • EXAS $59.40
  • Analyst Decision
  • ARCC Buy
  • EXAS Strong Buy
  • Analyst Count
  • ARCC 7
  • EXAS 16
  • Target Price
  • ARCC $22.29
  • EXAS $72.80
  • AVG Volume (30 Days)
  • ARCC 5.0M
  • EXAS 2.3M
  • Earning Date
  • ARCC 02-05-2025
  • EXAS 11-05-2024
  • Dividend Yield
  • ARCC 8.98%
  • EXAS N/A
  • EPS Growth
  • ARCC 11.92
  • EXAS N/A
  • EPS
  • ARCC 2.60
  • EXAS N/A
  • Revenue
  • ARCC $2,938,000,000.00
  • EXAS $2,692,328,000.00
  • Revenue This Year
  • ARCC $17.71
  • EXAS $11.81
  • Revenue Next Year
  • ARCC $3.67
  • EXAS $11.41
  • P/E Ratio
  • ARCC $8.23
  • EXAS N/A
  • Revenue Growth
  • ARCC 15.35
  • EXAS 11.91
  • 52 Week Low
  • ARCC $19.32
  • EXAS $40.62
  • 52 Week High
  • ARCC $22.44
  • EXAS $79.62
  • Technical
  • Relative Strength Index (RSI)
  • ARCC 42.56
  • EXAS 48.45
  • Support Level
  • ARCC $20.90
  • EXAS $55.65
  • Resistance Level
  • ARCC $21.46
  • EXAS $62.15
  • Average True Range (ATR)
  • ARCC 0.25
  • EXAS 2.41
  • MACD
  • ARCC -0.13
  • EXAS -0.26
  • Stochastic Oscillator
  • ARCC 31.17
  • EXAS 41.12

About ARCC Ares Capital Corporation

Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Share on Social Networks: